Haya Therapeutics is dedicated to advancing precision medicine by focusing on regulatory RNAs derived from the dark genome. The company's innovative approach aims to develop RNA-based therapies that can reprogram disease-driving cellular states, targeting conditions such as fibrotic diseases, cardiovascular issues, and metabolic disorders. Haya uses its proprietary technology to identify and manipulate long non-coding RNAs (lncRNAs) to prevent ...read more
hayatx.com
Samir Ounzain
CEO & Co-founder
Daniel Blessing
CTO & Co-founder